Percheron Therapeutics Ltd (PER) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Percheron Therapeutics Ltd (PER) has a cash flow conversion efficiency ratio of -0.716x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-7.16 Million ≈ $-5.07 Million USD) by net assets (AU$10.00 Million ≈ $7.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PER equity to assets ratio to measure how much of total assets are equity-financed.
Percheron Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Percheron Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PER operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Percheron Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Percheron Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jeffs' Brands Ltd
NASDAQ:JFBR
|
-0.295x |
|
Tri Banyan Tirta Tbk
JK:ALTO
|
0.004x |
|
N. Leventeris S.A.
AT:LEBEK
|
-0.132x |
|
Femto Technologies Inc.
NASDAQ:FMTO
|
0.483x |
|
Limas Indonesia Makmur Tbk
JK:LMAS
|
0.000x |
|
Site Group International Ltd
AU:SIT
|
0.088x |
|
Serabi Gold PLC
LSE:SRB
|
0.137x |
|
Liontrust Asset Management
LSE:LIO
|
0.056x |
Annual Cash Flow Conversion Efficiency for Percheron Therapeutics Ltd (2002–2025)
The table below shows the annual cash flow conversion efficiency of Percheron Therapeutics Ltd from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Percheron Therapeutics Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$10.00 Million ≈ $7.08 Million |
AU$-15.64 Million ≈ $-11.07 Million |
-1.564x | -44.74% |
| 2024-06-30 | AU$9.36 Million ≈ $6.62 Million |
AU$-10.12 Million ≈ $-7.16 Million |
-1.080x | -32.22% |
| 2023-06-30 | AU$9.98 Million ≈ $7.06 Million |
AU$-8.15 Million ≈ $-5.77 Million |
-0.817x | -121.33% |
| 2022-06-30 | AU$21.14 Million ≈ $14.96 Million |
AU$-7.81 Million ≈ $-5.52 Million |
-0.369x | +63.76% |
| 2021-06-30 | AU$5.73 Million ≈ $4.05 Million |
AU$-5.83 Million ≈ $-4.13 Million |
-1.019x | -16.98% |
| 2020-06-30 | AU$4.53 Million ≈ $3.21 Million |
AU$-3.95 Million ≈ $-2.79 Million |
-0.871x | +16.46% |
| 2019-06-30 | AU$2.81 Million ≈ $1.99 Million |
AU$-2.93 Million ≈ $-2.07 Million |
-1.042x | -91.14% |
| 2018-06-30 | AU$4.22 Million ≈ $2.99 Million |
AU$-2.30 Million ≈ $-1.63 Million |
-0.545x | +65.32% |
| 2017-06-30 | AU$1.85 Million ≈ $1.31 Million |
AU$-2.91 Million ≈ $-2.06 Million |
-1.572x | -255.40% |
| 2016-06-30 | AU$4.58 Million ≈ $3.24 Million |
AU$-2.03 Million ≈ $-1.43 Million |
-0.442x | -347.26% |
| 2015-06-30 | AU$7.09 Million ≈ $5.02 Million |
AU$1.27 Million ≈ $897.81K |
0.179x | +112.01% |
| 2014-06-30 | AU$2.09 Million ≈ $1.48 Million |
AU$-3.11 Million ≈ $-2.20 Million |
-1.489x | -144.27% |
| 2013-06-30 | AU$4.65 Million ≈ $3.29 Million |
AU$-2.83 Million ≈ $-2.00 Million |
-0.610x | -33.48% |
| 2012-06-30 | AU$5.27 Million ≈ $3.73 Million |
AU$-2.41 Million ≈ $-1.70 Million |
-0.457x | +50.63% |
| 2011-06-30 | AU$2.02 Million ≈ $1.43 Million |
AU$-1.87 Million ≈ $-1.32 Million |
-0.925x | +6.96% |
| 2010-06-30 | AU$1.34 Million ≈ $951.04K |
AU$-1.34 Million ≈ $-945.75K |
-0.994x | -18.94% |
| 2009-06-30 | AU$3.93 Million ≈ $2.78 Million |
AU$-3.28 Million ≈ $-2.32 Million |
-0.836x | -55.71% |
| 2008-06-30 | AU$6.33 Million ≈ $4.48 Million |
AU$-3.40 Million ≈ $-2.41 Million |
-0.537x | -20.59% |
| 2007-06-30 | AU$6.02 Million ≈ $4.26 Million |
AU$-2.68 Million ≈ $-1.90 Million |
-0.445x | +1.08% |
| 2006-06-30 | AU$8.79 Million ≈ $6.22 Million |
AU$-3.96 Million ≈ $-2.80 Million |
-0.450x | +12.43% |
| 2005-06-30 | AU$10.86 Million ≈ $7.69 Million |
AU$-5.59 Million ≈ $-3.95 Million |
-0.514x | -298.62% |
| 2004-06-30 | AU$17.13 Million ≈ $12.12 Million |
AU$-2.21 Million ≈ $-1.56 Million |
-0.129x | +57.16% |
| 2002-06-30 | AU$13.48 Million ≈ $9.54 Million |
AU$-4.06 Million ≈ $-2.87 Million |
-0.301x | -- |
About Percheron Therapeutics Ltd
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also devel… Read more